Speaker: Joaquim Bellmunt

Prof Joaquim Bellmunt

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

Long term outcomes in JAVELIN Bladder 100: avelumab in urothelial carcinoma

Bladder cancer: chemotherapy vs. immunotherapy

The Patients' Channel

Dr. Bellmunt on Immunotherapy Combination Trials in Bladder Cancer

Sequencing and treatment strategies in advanced urothelial carcinoma

Maintenance therapy for bladder cancer

IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC

Treatment options and their rollout for patients with metastatic urothelial carcinoma

How can we improve responses to immunotherapy in patients with bladder cancer?

Perioperative treatment strategies for high-risk bladder cancer

Current and upcoming clinical trials in bladder cancer

Highlights in bladder cancer from ASCO 2022

Highlights in bladder cancer at ESMO 2022

Emerging role of adjuvant immunotherapy in oncology

Updates in kidney cancer at ESMO 2022

When can checkpoint inhibitors be used to treat urothelial carcinoma?

KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma

JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer

The impact of mutational clonality on patient response to immunotherapies in UC